Curative surgical treatment after inefficient long-acting somatostatin analogues therapy of a tumor-induced osteomalacia;Efficacité du traitement chirurgical après échec des analogues de la somatostatine dans l'ostéomalacie oncogénique.

Presse Medicale

Volumn 40, Issue 3, 2011, Pages 309-313

  Mékinian, Arsene ^a   Ladsous, Miriam ^a   Balavoine, Anne Sophie ^a   Carnaille, Bruno ^a   Aubert, Sebastien ^a   Soudan, Benoît ^a   Wémeau, Jean Louis ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CREATININE; FIBROBLAST GROWTH FACTOR 23; LONG ACTING DRUG; OSTEOCALCIN; PARATHYROID HORMONE; PENTETREOTIDE; PHOSPHATE; SOMATOSTATIN RECEPTOR 2; TELOPEPTIDE;

ABDOMINAL PAIN; AGED; BONE DENSITY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONE BLOOD LEVEL; HUMAN; HYPOPHOSPHATEMIA; KIDNEY DISEASE; KIDNEY TUBULE ABSORPTION; LETTER; ONCOGENIC OSTEOMALACIA; OSTEOPENIA; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; PROTEIN BLOOD LEVEL; RIB FRACTURE; SALIVARY GLAND DISEASE; VERTEBRA FRACTURE; WHOLE BODY SCINTISCANNING;

ABSORPTIOMETRY, PHOTON; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; HEMANGIOPERICYTOMA; HUMANS; MAXILLARY NEOPLASMS; OCTREOTIDE; OSTEOMALACIA; PARANEOPLASTIC SYNDROMES; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79952574689     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.10.011     Document Type: Letter

References (19)

1. Folpe A.L., Fanburg-Smith J.C., Billings S.D., Bisceglia M., Bertoni F., Cho J.Y., et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004, 28:1-30.
2. Berndt J., Schiavi S., Kumar R. Phosphatonins and the regulation of phosphorus homeostasis. Am J Renal Physiol 2005, 289:1170-1182.
3. Poizat F., Wojtusciszin A., Raynaud P., Maite H., Renard E.R., Baldet P. Foot tumor and diffuse pain: a case of oncogenic osteomalacia. Ann Pathol 2005, 25:134-137.
4. Schapira D., Ben Izhak O., Nachtigal A., Burstein A., Shalom R.B., Best L.A. Tumor-induced osteomalacia. Semin Artritis Rheum 1995, 25:35-46.
5. Malabanan A.O., Turner A.K., Rosenberg I.N., Holick M.F. Oncogenic osteomalacia: clinical presentation, densitometric findings, and response to therapy. J Clin Densitom 1998, 1:77-80.
6. Jim Yeung S., McCutcheon I., Schultz P., Gagel R. Use of long-term intravenous phosphate infusion in the palliative treatment of tumor-induced osteomalacia. J Clin Endocrinol 2000, 5:549-555.
7. Saveanu A., Lavaque E., Gunz G., Barlier A., Kim S., Taylor J.E., et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002, 87:5545-5552.
8. Reid I.R., Teitelbaum S.L., Dusso A., Whyte M.P. Hypercalcemic hyperparathyroidism complicating oncogenic osteomalacia. Am J Med 1987, 83:350-354.
9. Huang Q.L., Feig D.S., Blackstein M. Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia. J Endocrinol Invest 2000, 23:263-267.
10. Seufert J., Ebert K., Muller J., Eulert J., Hendrich C., Jakob F., et al. Octreotide therapy for tumor-induced osteomalacia. NEJM 2004, 345:1883-1888.
11. Reubi J.C., Waser B., Laissue J.A., Gebbers J.O. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res 1996, 56:1922-1931.
12. Müssig K., Oksüz M.O., Pfannenberg C., Adam P., Zustin J., Beckert S., et al. Somatostatin receptor expression in an epitheloid hemangioma causing oncogenic osteomalacia. J Clin Endocrinol Metab 2009, 94:4123-4124.
13. Jan de Beur S., Streeten E.A., Civelek A.C., McCarthy E.F., Uribe L., Marx S.J., et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 2002, 359:761-763.
14. Duet M., Kerkeni S., Sfar R., Bazille C., Lioté F., Orcel P. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med 2008, 33:752-756.
15. Dupond J.L., Mahammeddi H., Prié D., Collin F., Gil H., Blagosklonov O., et al. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnostis and follow-up in one case. Bone 2005, 36:375-378.
16. Yoshioka K., Nagata R., Ueda M., Yamaguchi T., Konishi Y., Sato T., et al. Phosphaturic mesenchymal tumor with symptoms related to osteomalacia that appeared one year after tumorectomy. Intern Med 2006, 45:1157-1160.
17. Paglia F., Dionisi S., Minisola S. Octreotide for tumor-induced osteomalacia. NEJM 2002, 346:1748.
18. Elston M.S., Stewart I.J., Clifton R., Conaglen J.V. A case of oncogenic osteomalacia with preoperative secondary hyperparathyroidism: description of the biochemical response of FGF23 to octreotide therapy and surgery. Bone 2007, 40:236-241.
19. Jaquet P., Saveanu A., Gunz G., Fina F., Zamora A.J., Grino M., et al. Human somatostatin receptors subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify distinct tumoral phenotypes. J Clin Endocrinol Metab 2000, 85:781-792.